Infectious Diseases News and Research

RSS

CDC presents clinical trial results of Biojector 2000 at 13th Annual Conference on Vaccine Research

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems (NFITS), today announced that the Centers for Disease Control and Prevention (CDC) and its collaborating institutions presented the latest results of its clinical trial of the Biojector® 2000 at the 13th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Bethesda, Maryland April 26 - 28, 2010.

30 Apr 2010

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Gen-Probe Incorporated today reported financial results for the first quarter of 2010, highlighted by $135.4 million of total revenues and earnings per share of $0.48 on both a non-GAAP and GAAP basis.

30 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it received approval for its AUTOMAGLIA 90 fully-automated ECLIA analyzer as well as Down Syndrome screening kit from the State Food and Drug Administration of China.

29 Apr 2010

Preventing HPV infection could slow HIV epidemic, say researchers

Men infected with human papillomavirus are at greater risk of becoming infected with human immunodeficiency virus than men who are not HPV positive, according to researchers at the University of North Carolina at Chapel Hill.

29 Apr 2010

Cambodia closes 64.9 percent of illegal pharmacies

In a major crackdown, Cambodia has forced nearly 65 percent of illegal pharmacies operating in the country to close within the past five months. Led by an Inter-Ministerial Committee to Fight against Counterfeit & Substandard Medicines (IMC), the shops were targeted because of evidence that they were among the primary sources of substandard and counterfeit medicines in the country.

29 Apr 2010

Tulane University researchers urge action to eliminate malaria from Hispaniola

In an editorial in the May 2010 issue of the journal The Lancet Infectious Diseases, Tulane University malaria researchers urge action to eliminate malaria from Hispaniola, the last island in the Caribbean where the disease occurs regularly.

29 Apr 2010

Study examines lifestyle-related causes of death in AIDS patients

The study, by researchers from the University of Bristol and a large group of international collaborators, examined data from the Antiretroviral Therapy Cohort Collaboration (ART-CC) which involved nearly 40,000 patients who started ART between 1996 and 2006 in Europe and North America.

29 Apr 2010

China lifts decades-old HIV/AIDS travel ban

Late Tuesday, China's State Council lifted a decades-old restriction that banned foreigners with HIV/AIDS from entering the country, Reuters reports (Buckley, 4/27). The amended rules, which appear on the government website, also lift a travel ban on foreigners with other sexually transmitted diseases and leprosy, and "narrow the travel restriction on people with tuberculosis, to those with an infectious form of the lung disease," according to Bloomberg Businessweek (Randall, 4/28).

29 Apr 2010

New study reinforces urgent need for life-saving vaccines in Africa

A new study released this week in The Lancet Infectious Diseases finds that African children who contract pneumococcus - a bacterial infection that causes pneumonia, meningitis and sepsis - are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death.

29 Apr 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Causes of death in AIDS patients

New research shows that Antiretroviral Therapy (ART) continues to dramatically reduce rates of mortality from HIV infection in high-income countries, such that non-AIDS-related deaths exceed AIDS deaths after approximately four years of taking ART.

28 Apr 2010

China lifts ban on tourists suffering from HIV/AIDS

In a new development China has lifted its decades old reservations towards travelers and tourists suffering from HIV and AIDS in the wake of the Shanghai World Expo this weekend.

28 Apr 2010

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Prime-boost malaria vaccine regimen provides sterile protection: Vical

Vical Incorporated announced today that a prime-boost malaria vaccine regimen provided sterile protection, with no disease symptoms and no detectable malaria parasites, in 4 of 15 vaccinated volunteers a full 28 days after challenge with multiple infected-mosquito bites.

27 Apr 2010

Medivir rights offering to raise approximately SEK 325 million

The Board of Directors has resolved on the terms for the rights offering, that the Board of Directors on 28 March 2010 resolved, subject to approval by the Annual General Meeting. For every share held in Medivir, regardless of share class, the holder is entitled to one subscription right. Four subscription rights entitle the holder to subscribe for one new class B share.

27 Apr 2010

Researchers synthesize metal compounds that can be effective in treatment of cancer

Scientists from Bochum have managed to accurately determine the location of metal complexes within living cancer cells using Raman microscopy. The researchers have thus gained new insights into the mechanism of action of metal-containing drugs, to which they ascribe great potential capacities, e.g. in the treatment of cancer.

26 Apr 2010

Enhancing residence time improves drug effectivity: Study

Studies led by Stony Brook University professor of chemistry Peter J. Tonge indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents.

26 Apr 2010

Symphogen's Sympress II technology demonstrates cost-effective single batch production of rpAb

Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print] demonstrating the ability of its Sympress II technology to enable cost-effective production of recombinant polyclonal antibodies (rpAb) and antibody mixtures with batch-to-batch consistency that the Company believes could supply drug product for large indications such as cancer and infectious disease.

26 Apr 2010

Infectious Diseases News and Research

CDC presents clinical trial results of Biojector 2000 at 13th Annual Conference on Vaccine Research

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

Preventing HPV infection could slow HIV epidemic, say researchers

Cambodia closes 64.9 percent of illegal pharmacies

Tulane University researchers urge action to eliminate malaria from Hispaniola

Study examines lifestyle-related causes of death in AIDS patients

China lifts decades-old HIV/AIDS travel ban

New study reinforces urgent need for life-saving vaccines in Africa

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Causes of death in AIDS patients

China lifts ban on tourists suffering from HIV/AIDS

Study results from US Military Malaria Vaccine Program announced

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Prime-boost malaria vaccine regimen provides sterile protection: Vical

Medivir rights offering to raise approximately SEK 325 million

Researchers synthesize metal compounds that can be effective in treatment of cancer

Enhancing residence time improves drug effectivity: Study

Symphogen's Sympress II technology demonstrates cost-effective single batch production of rpAb

NGS for Infectious Disease Surveillance eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News